Expertise in
3
conditions

Dr. Charles J. Rosser

Urology
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
3
conditions
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 

Overview

Charles Rosser is a Urologist practicing medicine in West Hollywood, California.

Dr. Rosser is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 118 peer reviewed articles and participating in 13 clinical trials.

Specialties

Urology

Licenses

Urology in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Cedars-Sinai Medical Center
8700 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Enrollment Status: Recruiting
Publish Date: February 04, 2026
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2026
Intervention Type: Biological
Study Drugs: Bacillus of Calmette-Guerin, ALT-803
Study Phase: Phase 1/Phase 2
A Novel Multiplex Immunoassay for the Early Detection of Bladder Cancer
A Novel Multiplex Immunoassay for the Early Detection of Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2026
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: ALT-803, Bacillus Calumette-Guerin
Study Phase: Phase 2/Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
Radiogenomics of Muscle Invasive Bladder Cancer
Radiogenomics of Muscle Invasive Bladder Cancer
Enrollment Status: Terminated
Publish Date: April 18, 2024
Intervention Type: Diagnostic test
Study Phase: Not Applicable
View 8 Less Clinical Trials

118 Total Publications

A bladder cancer-associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer.
A bladder cancer-associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer.
Journal: Journal of translational medicine
Published: April 23, 2026
Similar Doctors
Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Office

1516 San Pablo St Ste 3500, 
Los Angeles, CA 
 (9.9 miles away)
323-865-3700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Siamak Daneshmand is a Urologist practicing medicine in Los Angeles, California. Dr. Daneshmand is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Testicular Cancer, Cystectomy, and Bladder Reconstruction.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

USC Norris Comprehensive Cancer Center And Hospital

1441 Eastlake Ave, 
Los Angeles, CA 
 (10.2 miles away)
323-865-3700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hooman Djaladat is a Urologist practicing medicine in Los Angeles, California. Dr. Djaladat is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Office

200 Medical Plz, 
Los Angeles, CA 
 (3.8 miles away)
310-794-7700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Karim Chamie is a Urologist practicing medicine in Los Angeles, California. Dr. Chamie is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Cystectomy.

Frequently Asked Questions about Dr. Charles J. Rosser

How do I make an appointment with Dr. Charles J. Rosser?

You can book an appointment with Dr. Charles J. Rosser by calling their office at 310-423-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Charles J. Rosser a top-rated expert for Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Charles J. Rosser is classified as an Elite expert for Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Charles J. Rosser specialize in?

While Dr. Charles J. Rosser is a Urology, they have specific expertise in Bladder Cancer, Urothelial Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Charles J. Rosser participate in research or clinical trials?

Yes. Dr. Charles J. Rosser has published 118 articles and abstracts on conditions like Bladder Cancer. You can view a list of Dr. Charles J. Rosser's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Charles J. Rosser accept my insurance?

Dr. Charles J. Rosser accepts most major insurance plans, including Blue Cross Blue Shield and Health Net. We recommend calling the office directly at 310-423-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosser's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile